squamous

Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.

Hexylresorcinol (4-Hexylresorcinol) is a substituted dihydroxybenzene utilized topically as an antiseptic for minor skin infection treatment.

Embelin (Embelic acid), isolated from the Japanese Ardisia herb, is an inhibitor of the X-linked inhibitor of apoptosis (IC50: 4.1 uM).

EF24 (3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone) treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK. EF24 shows potent anti-tumor activity in oral squamous cell carcinoma (OSCC) via deactivation of the MAPK ERK signaling pathway.

Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.

Pulrodemstat (CC-90011) is an orally active, selective, and highly efficient lysine-specific demethylase-1 (LSD1) inhibitor with anticancer activity. It inhibits HNSCC cell proliferation and migration by triggering apoptosis and inhibiting head and neck squamous cell carcinoma growth.

ABI-1968 PM is a derivative of ABI-1968, an apoptosis-stimulating agent and an inhibitor of viral replication.ABI-1968 can be used to study cervical intraepithelial neoplasia, papillomavirus infection, and squamous intraepithelial lesions.

USP28-IN-3 is a highly selective USP28 inhibitor with an IC50 value of 0.1 μM against USP28.USP28-IN-3 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3, and UCHL5.USP28-IN-3 is cytotoxic to human colorectal and lung squamous carcinoma cells, inhibiting c-cells and c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-cells through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.

Prinaberel (ERB 041) is a selective and potent estrogen receptor β (ERβ) agonist with anticancer activity that restores or increases ERβ expression and reduces cancer cell proliferation in mouse squamous cell carcinoma and human carcinoma cells. Prinaberel exhibits anti-inflammatory activity, inhibits the NFκB pro-inflammatory signaling pathway, and induces apoptosis of ovarian cancer cells. study endometriosis.

Isobutyl decanoate (Decanoic acid isobutyl ester) can be used as a biomarker for esophageal squamous cell carcinoma and lung cancer, and can be isolated from wine.

Pulrodemstat HCl is an orally active, selective and potent lysine demethylase-1 (LSD1) inhibitor, and a selective KDM1A inhibitor, with anticancer and anti-proliferative activities, inhibiting HNSCC cell proliferation and migration Inhibits the growth of head and neck squamous cell carcinoma by triggering apoptosis.

PFK-015 (PFK15) is an effective inhibitor of PFKFB3 (IC50: 110 nM) and inhibits PFKFB3 activity in Y cells (IC50: 20 nM).

LGK974 (NVP-LGK974) is an effective and selective PORCN inhibitor and inhibits Wnt signaling (IC50: 0.4 nM) in TM3 cells. It has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.

Chlorin E6 (CE6) is a second-generation photosensitizer with antitumor activity when used in combination with irradiation. In a mouse model of implanted fibrosarcoma, Chlorin E6 (2.5-10 mg kg, i.v., 50-200 J cm2 irradiation) resulted in complete tumor disappearance after varying degrees of irradiation. Agents including Chlorin E6 were tested in a Phase I clinical study in patients with early superficial squamous cell carcinoma of bronchial origin with favorable results (40 mg m2, IV, 100 J cm2 laser irradiation). In a Phase II clinical trial in patients with early stage lung cancer, the same mode of administration resulted in a complete response in 82.9% of patients. Chlorin E6 has been investigated as a nanotechnology drug delivery tool.

Canertinib (CI-1033) is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

IV-23, a potent inhibitor of cell growth both in vitro and in vivo, effectively reduces colony formation, arrests the cell cycle at the M phase, and induces apoptosis in esophageal squamous cell carcinoma through Noxa-mediated pathways. This compound emerges as a promising anticancer agent with significant potential.

L-NIL is a selective nitric oxide synthase (iNOS) inhibitor that reverses burn-induced activation of glycogen synthase kinase-3β in rat skeletal muscle and may slow the progression of squamous cell carcinoma lung.

RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3 nM.

CCT129957 is a novel and potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of about 3 μM and a GC50 of 15 μM.CCT129957 exhibits anticancer activity and inhibits Ca2+ release in squamous cells.

Lobaplatin (D-19466) (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin (D-19466) is a third-generation platinum anti-neoplastic agent which shows activity for a variety of tumour types and is a promising antitumour chemotherapeutic agent[1][2]. It is a platinum complex with DNA alkylating activity.

NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities

Temoporfin used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck.

Bleomycin A6 (also known as boanmycin) is utilized in trials for treating squamous cell lung cancer. Studies indicate that Bleomycin A6 not only exhibits antitumor effects but also modifies the tumor microenvironment, which may contribute to the recurrence and metastasis of lung cancer during prolonged treatment.

PROTAC LZK-IN-1 (Compound 21A) is a PROTAC molecule that targets the degradation of LZK (leucine zipper kinase, encoded by MAP3K13). At a concentration of 10 μM, PROTAC LZK-IN-1 facilitates the degradation of LZK and inhibits the expression of p53 and c-MYC, leading to reduced viability of global head and neck squamous cell carcinoma (HNSCC) cell lines. This compound is applicable in anticancer research.